<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39427983</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1089-8638</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of molecular biology</Title><ISOAbbreviation>J Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Engineered mRNAs with stable structures minimize double-stranded RNA formation and increase protein expression.</ArticleTitle><Pagination><StartPage>168822</StartPage><MedlinePgn>168822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmb.2024.168822</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-2836(24)00444-3</ELocationID><Abstract><AbstractText>The therapeutic use of synthetic message RNA (mRNA) has been validated in COVID-19 vaccines and shows enormous potential in developing infectious and oncological vaccines. However, double-stranded RNA (dsRNA) byproducts generated during the in vitro transcription (IVT) process can diminish the efficacy of mRNA-based therapeutics and provoke innate immune responses. Existing methods to eliminate dsRNA byproducts are often cumbersome and labor-intensive. In this study, we revealed that a loose mRNA secondary structure and more unpaired U bases in the sequence generally lead to the formation of more dsRNA byproducts during the IVT process. We further developed a predictive model for dsRNA byproducts formation based on sequence characteristics to guide the optimization of mRNA sequences, helping to minimize unwanted immune response and improve the protein expression of mRNA products. Collectively, our study provides novel clues and methodologies for developing effective mRNA therapeutics with minimized dsRNA byproducts and increased protein expression.</AbstractText><CopyrightInformation>Copyright Â© 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Qianshan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Huanhua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Weixiang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Ruyin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guopeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaojing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Niangang</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China. Electronic address: peng.gao@abogenbio.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China. Electronic address: qiliu@tongji.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Mol Biol</MedlineTA><NlmUniqueID>2985088R</NlmUniqueID><ISSNLinking>0022-2836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA immunogenicity</Keyword><Keyword MajorTopicYN="N">RNA purification</Keyword><Keyword MajorTopicYN="N">double-stranded RNA</Keyword><Keyword MajorTopicYN="N">in vitro expression</Keyword><Keyword MajorTopicYN="N">in vitro transcription</Keyword><Keyword MajorTopicYN="N">mRNA secondary structure</Keyword><Keyword MajorTopicYN="N">messenger RNA</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427983</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2024.168822</ArticleId><ArticleId IdType="pii">S0022-2836(24)00444-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>